Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders.
April has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, AdventHealth and DexCare both named new CEOs, and…
Several states and insurers have gold carding programs to streamline prior authorization. However, some say they’re falling short.
The mandatory CMS TEAM program begins next year. Are you ready? As hospitals consider their options for addressing the mandate, here are some actions to…
In this episode, we’re joined by Maggie McCullough, CEO of PolicyMap. She discusses what’s wrong with the way maternal health data is collected at the…
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need…
By shifting the focus for consumers earlier in the care continuum, AI has the potential to play a transformative role in prevention and personalized health…
The country’s nursing workforce has seen slight recovery since the pandemic, but burnout and stress continue to fuel high levels of turnover. New research reveals…
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform.
During a recent panel, hospital leaders discussed how they approach the balancing act between innovation and financial sustainability. They shared tactics such as reassessing vendor…
Abeona Therapeutics makes Zevaskyn by engineering a patient’s biopsied skin cells to express the collagen that they lack, then growing those cells into sheets that…
